We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.00 | 1.90% | 1,766.50 | 1,766.50 | 1,767.00 | 1,767.00 | 1,736.00 | 1,736.00 | 2,504,623 | 14:56:32 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.76 | 72.73B |
From May 2019 to May 2024
TIDMGSK
RNS Number : 1946F
GlaxoSmithKline PLC
16 February 2018
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
This notification sets out the vesting details of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2015 under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan ('DABP') and the associated Matching Awards, which were subject to relevant business performance conditions. The three-year performance period for the 2015 Matching Awards commenced on 1 January 2015 and ended on 31 December 2017 and the restricted period has come to an end.
The performance measure vesting details are as follows:
Hot Features
Premium
Outcome and
Vesting Level
----------------------------------------------- ------------------
Portion Measure and Outcome % of % of
of the maximum award
Award
--------- ------------------------------------ --------- -------
Adjusted Free Cash Flow -
For the three-year period,
the Company achieved Adjusted
Free Cash Flow calculated
in accordance with the principles
for the measure of GBP12.47bn
which is above the threshold
1/3(rd) level of GBP11.48bn. 63 21
--------- ------------------------------------ --------- -------
Total Shareholder Return
- For the three years ending
31 December 2017, the Company's
Total Shareholder Return
ranked 5(th) , which is above
the threshold vesting level
against a comparator group
of 10 global pharmaceutical
1/3(rd) companies including GSK. 44 14.67
--------- ------------------------------------ --------- -------
R&D New Products - For the
three-year period, the Company
achieved New Product sales
calculated in accordance
with the principles for the
measure of GBP11.266bn, which
is above the maximum vesting
level of GBP7.912bn (the
1/3(rd) threshold level was GBP6.474bn). 100 33.33
--------- ------------------------------------ --------- -------
Total vesting for 2015 award 69%
Lapsed 31%
--------------------------------------------------------- -------
The notifications that follow are for awards made to Persons Discharging Managerial Responsibilities ('PDMRs'). They show the vesting of the Deferred Bonus Awards including dividends accrued, and the proportion vesting of the associated Matching Awards i.e., conditional awards that vested according to performance, including dividends accrued on those vesting shares, on 15 February 2018. The balance of these awards made to each PDMR has lapsed.
The closing prices of an Ordinary Share and of an ADS of GlaxoSmithKline plc at the point of vesting on 15 February 2018 were GBP13.004 and $37.31 respectively.
Transaction notification
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Ms E Walmsley
=== ====================== ====================================
b) Position/status Chief Executive Officer
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 12,482 (Deferred)
--------- ------------------
GBP0.00 8,614 (Matching)
--------- ------------------
=== ====================== ====================================
d) Aggregated
information 21,096
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Mr R Connor
=== ====================== ====================================
b) Position/status President, Global Manufacturing
& Supply
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
GBP0.00 9,142 (Deferred)
--------- -----------------
GBP0.00 6,308 (Matching)
--------- -----------------
=== ====================== ====================================
d) Aggregated
information 15,450
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Mr S Dingemans
=== ====================== ====================================
b) Position/status Chief Financial Officer
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 17,435 (Deferred)
--------- ------------------
GBP0.00 12,030 (Matching)
--------- ------------------
=== ====================== ====================================
d) Aggregated
information 29,465
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Mr D Redfern
=== ====================== ====================================
b) Position/status Chief Strategy Officer
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 10,258 (Deferred)
--------- ------------------
GBP0.00 7,078 (Matching)
--------- ------------------
=== ====================== ====================================
d) Aggregated
information 17,336
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Ms C Thomas
=== ====================== ====================================
b) Position/status SVP, Human Resources
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 13,805 (Deferred)
--------- ------------------
GBP0.00 9,525 (Matching)
--------- ------------------
=== ====================== ====================================
d) Aggregated
information 23,330
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Mr P Thomson
=== ====================== ====================================
b) Position/status President, Global Affairs
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
GBP0.00 4,689 (Deferred)
--------- -----------------
GBP0.00 3,235 (Matching)
--------- -----------------
=== ====================== ====================================
d) Aggregated
information 7,924
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
==== =============================================================
a) Name Mr D Troy
==== ======================= ====================================
b) Position/status SVP & General Counsel
==== ======================= ====================================
c) Initial notification/ Initial notification
amendment
==== ======================= ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
==== =============================================================
a) Name GlaxoSmithKline plc
==== ======================= ====================================
b) LEI 5493000HZTVUYLO1D793
==== ======================= ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
==== =============================================================
a) Description GlaxoSmithKline plc American
of the financial Depositary Shares ('ADSs')
instrument ISIN: US37733W1053
==== ======================= ====================================
b) Nature of The number of ADSs released on
the transaction awards granted in 2015 under
the Company's 2009 Deferred Annual
Bonus Plan--Deferred Bonus and
Matching Awards.
==== ======================= ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
$0.00 7,338 (Deferred)
--------- -----------------
$0.00 5,062 (Matching)
--------- -----------------
==== ======================= ====================================
Aggregated
information
Aggregated
d) volume Price 12,400 $0.00
==== ======================= ====================================
e) Date of the 2018-02-15
transaction
==== ======================= ====================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================= ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Dr P Vallance
=== ====================== ====================================
b) Position/status Outgoing President, R&D
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2015 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ------------------
GBP0.00 20,322 (Deferred)
--------- ------------------
GBP0.00 14,022 (Matching)
--------- ------------------
=== ====================== ====================================
d) Aggregated
information 34,344
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
1. Details of PDMR/person closely associated
with them ('PCA')
=== ============================================================
a) Name Mr Nick Hirons
=== ====================== ====================================
b) Position/status SVP, Global Ethics and Compliance
=== ====================== ====================================
c) Initial notification/ Initial notification
amendment
=== ====================== ====================================
2. Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
=== ============================================================
a) Name GlaxoSmithKline plc
=== ====================== ====================================
b) LEI 5493000HZTVUYLO1D793
=== ====================== ====================================
3. Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transaction(s)
has been conducted
=== ============================================================
a) Description Ordinary shares of 25 pence each
of the financial ('Ordinary Shares')
instrument ISIN: GB0009252882
=== ====================== ====================================
b) Nature of The number of Ordinary Shares
the transaction released on awards granted in
2014 under the Company's 2009
Deferred Annual Bonus Plan-Deferred
Bonus and Matching Awards.
=== ====================== ====================================
c) Price(s) and Price(s) Volume(s)
volume(s) --------- -----------------
GBP0.00 6,402 (Deferred)
--------- -----------------
GBP0.00 4,418 (Matching)
--------- -----------------
=== ====================== ====================================
d) Aggregated
information 10,820
Aggregated GBP0.00
volume
Price
=== ====================== ====================================
e) Date of the 2018-02-15
transaction
=== ====================== ====================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ====================== ====================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHDQLFFVLFLBBV
(END) Dow Jones Newswires
February 16, 2018 12:29 ET (17:29 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
